• Je něco špatně v tomto záznamu ?

Bipolar disorders, type 2 diabetes mellitus, and the brain

T. Hajek, R. McIntyre, M. Alda,

. 2016 ; 29 (1) : 1-6.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027952

PURPOSE OF REVIEW: Type 2 diabetes mellitus (T2DM) negatively affects brain structure and function. Meta-analytical data show that relative to age and sex matched non-psychiatric controls, patients with bipolar disorders have double the risk of T2DM. We review the evidence for association between T2DM and adverse clinical and brain imaging changes in bipolar disorders and summarize studies investigating effects of diabetes treatment on psychiatric and brain outcomes. RECENT FINDINGS: Participants with bipolar disorders and T2DM or insulin resistance demonstrate greater morbidity, chronicity and disability, and lower treatment response to Li. Bipolar disorders complicated by insulin resistance/T2DM are associated with smaller hippocampal and cortical gray matter volumes and lower prefrontal N-acetyl aspartate (neuronal marker). Treatment of T2DM yields preservation of brain gray matter and insulin sensitizers, such as pioglitazone, improve symptoms of depression in unipolar or bipolar disorders. SUMMARY: T2DM or insulin resistance frequently cooccur with bipolar disorders and are associated with negative psychiatric clinical outcomes and compromised brain health. This is clinically concerning, as patients with bipolar disorders have an increased risk of metabolic syndrome and yet often receive suboptimal medical care. At the same time treatment of T2DM and insulin resistance has positive effects on psychiatric and brain outcomes. These findings create a rich agenda for future research, which could enhance psychiatric pharmacopeia and directly impact patient care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027952
003      
CZ-PrNML
005      
20161021111806.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/YCO.0000000000000215 $2 doi
024    7_
$a 10.1097/YCO.0000000000000215 $2 doi
035    __
$a (PubMed)26575297
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hajek, Tomas $u aDepartment of Psychiatry, Dalhousie University, Halifax, CanadabNational Institute of Mental Health, Klecany, Czech RepubliccDepartment of Psychiatry, University of Toronto, Toronto, Canada.
245    10
$a Bipolar disorders, type 2 diabetes mellitus, and the brain / $c T. Hajek, R. McIntyre, M. Alda,
520    9_
$a PURPOSE OF REVIEW: Type 2 diabetes mellitus (T2DM) negatively affects brain structure and function. Meta-analytical data show that relative to age and sex matched non-psychiatric controls, patients with bipolar disorders have double the risk of T2DM. We review the evidence for association between T2DM and adverse clinical and brain imaging changes in bipolar disorders and summarize studies investigating effects of diabetes treatment on psychiatric and brain outcomes. RECENT FINDINGS: Participants with bipolar disorders and T2DM or insulin resistance demonstrate greater morbidity, chronicity and disability, and lower treatment response to Li. Bipolar disorders complicated by insulin resistance/T2DM are associated with smaller hippocampal and cortical gray matter volumes and lower prefrontal N-acetyl aspartate (neuronal marker). Treatment of T2DM yields preservation of brain gray matter and insulin sensitizers, such as pioglitazone, improve symptoms of depression in unipolar or bipolar disorders. SUMMARY: T2DM or insulin resistance frequently cooccur with bipolar disorders and are associated with negative psychiatric clinical outcomes and compromised brain health. This is clinically concerning, as patients with bipolar disorders have an increased risk of metabolic syndrome and yet often receive suboptimal medical care. At the same time treatment of T2DM and insulin resistance has positive effects on psychiatric and brain outcomes. These findings create a rich agenda for future research, which could enhance psychiatric pharmacopeia and directly impact patient care.
650    _2
$a bipolární porucha $x krev $x metabolismus $x patologie $x psychologie $7 D001714
650    _2
$a mozek $x patologie $x patofyziologie $7 D001921
650    _2
$a deprese $x farmakoterapie $x etiologie $7 D003863
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $x patologie $x patofyziologie $x psychologie $7 D003924
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    12
$a inzulinová rezistence $7 D007333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a McIntyre, Roger
700    1_
$a Alda, Martin $7 xx0072985
773    0_
$w MED00001294 $t Current opinion in psychiatry $x 1473-6578 $g Roč. 29, č. 1 (2016), s. 1-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26575297 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161021112214 $b ABA008
999    __
$a ok $b bmc $g 1166266 $s 952582
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 29 $c 1 $d 1-6 $i 1473-6578 $m Current opinion in psychiatry $n Curr Opin Psychiatry $x MED00001294
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...